Effects of adding extended-release XXXX and @entity35277 to statin therapy on lipid levels in subjects with @entity731 .

@entity1 @entity35277 @entity2299 @entity2993 @entity1670 @entity1780 @entity731 @entity121 @entity165
BACKGROUND: The use of combination therapies is needed to treat @entity2299 in @entity1 with both elevated low-density lipoprotein @entity165 (LDL-C) and low high-density lipoprotein @entity165 (HDL-C). We conducted a study to assess the efficacy and safety of combination therapy with @entity1780 plus extended-release (ER) @entity1670 and @entity35277 , aimed at lowering LDL-C and raising HDL-C, in subjects with @entity731 . METHODS: This 1-year study randomized 123 subjects with @entity731 to @entity2993 alone, double therapy with @entity2993 plus ER @entity1670 , or triple therapy with @entity2993 , plus ER @entity1670 and @entity35277 . Target LDL-C was  <=80 mg/dL for single and double therapy, and  <=60 mg/dL for triple therapy. Target HDL-C was an increase of >= 10 mg/dL for double and triple therapy. RESULTS: Single therapy, with mean @entity2993 dose 30 mg/day, had a 47% reduction in LDL-C (P < 0.001) from 148    29 mg/dL to 77    15 mg/dL. With the addition of ER @entity1670 , the double therapy had a 25% increase in HDL-C, from 42    11 mg/dL to 53    16 mg/dL (P < 0.001). The triple therapy decreased LDL-C by 57%, from 157    29 mg/dL to 66    18 mg/dL (P < 0.001), and increased HDL-C by 29%, from 40    9 mg/dL to 50    14 mg/dL (P < 0.001). Double and triple therapy required a lower @entity2993 dose of 20 mg/day to reach the target LDL-C levels. On average, 75% and 67% of subjects reached the predefined LDL-C and HDL-C treatment targets. No related @entity121 or hepatotoxicity required stopping the therapy. CONCLUSION: This study demonstrated that combination therapy with @entity2993 plus ER @entity1670 and @entity35277 can safely and effectively treat @entity2299 in subjects with @entity731 .
